Ocular Therapeutix (OCUL) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month target prices for Ocular Therapeutix's stock. Their OCUL share price forecasts range from $10.00 to $18.00. On average, they predict the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 95.1% from the stock's current price.
View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts.

Ocular Therapeutix's stock was trading at $2.81 at the beginning of the year. Since then, OCUL stock has increased by 146.3% and is now trading at $6.92.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our OCUL earnings forecast.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Monday, March, 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. The biopharmaceutical company earned $14.08 million during the quarter, compared to the consensus estimate of $13.60 million. Ocular Therapeutix had a negative net margin of 171.85% and a negative trailing twelve-month return on equity of 213.57%.

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Raymond James SB-1 Equity ETF (RYJ), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ).

Ocular Therapeutix issued an update on its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $55.00 million-$60.00 million, compared to the consensus revenue estimate of $58.80 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.34%), Deltec Asset Management LLC (2.47%), State Street Corp (1.93%), Geode Capital Management LLC (1.88%), Cetera Investment Advisers (0.78%) and Two Sigma Investments LP (0.42%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends.

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OCUL stock can currently be purchased for approximately $6.92.

Ocular Therapeutix (NASDAQ:OCUL) has a market capitalization of $536.47 million and generates $51.68 million in revenue each year. The biopharmaceutical company earns $-71,040,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

The company employs 228 workers across the globe.

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The official website for the company is www.ocutx.com. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at chris.brinzey@westwicke.com, or via fax at 781-357-4001.